{"id":97423,"date":"2025-05-27T00:00:00","date_gmt":"2025-05-27T00:00:00","guid":{"rendered":"https:\/\/enterpriseam.com\/ksa\/2025\/05\/27\/smc-postpones-retail-subscription-period-to-mid-june\/"},"modified":"2025-05-27T00:00:00","modified_gmt":"2025-05-27T00:00:00","slug":"smc-postpones-retail-subscription-period-to-mid-june","status":"publish","type":"post","link":"https:\/\/enterpriseam.com\/ksa\/2025\/05\/27\/smc-postpones-retail-subscription-period-to-mid-june\/","title":{"rendered":"SMC postpones retail subscription period to mid-June"},"content":{"rendered":"

<\/strong>Specialized <\/strong>Medical Company\u2019s (SMC) IPO retail subscription was pushed <\/strong>back to<\/strong> 15-16 June<\/strong>, while the final price will be made public on Tuesday, 3 June, according to a complimentary prospectus (pdf)<\/a>. The two-day retail subscription period was initially scheduled to start tomorrow. The final allocation of shares is now slated for Tuesday, 24 June, instead of the earlier 4 June date, the document said.<\/p>\n

(** Tap or click the headline above to read this story with all of the links<\/strong> to our background and outside sources.)<\/p>\n

ICYMI- <\/strong>SMC\u2019s institutional offering sold out within hours of opening earlier this month<\/a>, with demand clearing the book across the full price range. The private healthcare provider is guiding on a price range of SAR 24-25 per share for its main market IPO, which will see it put a 30% stake on offer in a secondary share sale.<\/p>\n

Proceeds + market cap: <\/strong>At the top of the range, the IPO could raise up to SAR 1.9 bn (USD 500 mn) for selling shareholders, giving the Riyadh-based private healthcare provider a market cap of SAR 6.3 bn (USD 1.7 bn) at listing.<\/p>\n

One of the largest IPOs this year:<\/strong> While Flynas\u2019 SAR 4.1 bn listing<\/a> is expected to secure the title for the biggest IPO of the year, SMC\u2019s offering is poised to be the third-largest listing on the main market so far this year \u2014 landing between Umm Al Qura for Development\u2019s SAR 2 bn IPO<\/a> in March and Almoosa Health\u2019s SAR 1.7 bn debut<\/a> in January.<\/p>\n

ADVISORS-<\/strong> Our friends at EFG Hermes are quarterbacking the transaction as joint financial advisors, underwriters, and bookrunners, alongside SNB Capital. SNB Capital is also serving as lead manager, with White & Case providing counsel to the issuer. Receiving agents include Al Rajhi Capital, BSF Capital, Alinma Investment, and Riyad Capital, among others.<\/p>\n

ALSO IN THE PIPELINE-<\/strong><\/p>\n